Ionis Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.About IONS
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T.
CEOBrett P. Monia
CEOBrett P. Monia
Employees1,069
Employees1,069
HeadquartersCarlsbad, California
HeadquartersCarlsbad, California
Founded1989
Founded1989
Employees1,069
Employees1,069
IONS Key Statistics
Market cap11.72B
Market cap11.72B
Price-Earnings ratio-39.72
Price-Earnings ratio-39.72
Dividend yield—
Dividend yield—
Average volume2.32M
Average volume2.32M
High today$73.90
High today$73.90
Low today$72.30
Low today$72.30
Open price$73.55
Open price$73.55
Volume1.40M
Volume1.40M
52 Week high$74.42
52 Week high$74.42
52 Week low$23.95
52 Week low$23.95
IONS News
The Motley Fool 4h
Capricorn Buys New Stake in Ionis Pharmaceuticals With 163,000 SharesOn October 17, 2025, Capricorn Fund Managers Ltd disclosed a new stake in Ionis Pharmaceuticals, acquiring approximately 162,800 shares in a trade estimated at...
Simply Wall St 13h
Ionis Pharmaceuticals: How Does Valuation Stack Up Following Revenue Surge and Upbeat 2025 Guidance?Ionis Pharmaceuticals (IONS) recently delivered second quarter results with revenue doubling year over year. The company also raised its full-year revenue guida...
Simply Wall St 2d
Should Ionis Pharmaceuticals' Raised Revenue Guidance and Strong Q2 Results Prompt Investor Action?Ionis Pharmaceuticals recently reported that its second quarter 2025 revenue doubled year-over-year to US$452 million and raised its full-year 2025 revenue guid...
Analyst ratings
74%
of 27 ratingsBuy
74.1%
Hold
25.9%
Sell
0%
More IONS News
TipRanks 5d
Ionis Pharmaceuticals price target raised to $90 from $86 at Morgan StanleyMorgan Stanley raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $90 from $86 and keeps an Overweight rating on the shares. The firm’s estimates...
People also own
Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.